Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial

Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC). Preclinical evidence suggests that the sequential administration of IRI and FU produces synergistic activity, although their clinical use has not been fully...

Descripción completa

Detalles Bibliográficos
Autores principales: Barone, C, Landriscina, M, Quirino, M, Basso, M, Pozzo, C, Schinzari, G, Leonardo, G Di, D'Argento, E, Trigila, N, Cassano, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360198/
https://www.ncbi.nlm.nih.gov/pubmed/17164761
http://dx.doi.org/10.1038/sj.bjc.6603496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360198/
https://www.ncbi.nlm.nih.gov/pubmed/17164761
http://dx.doi.org/10.1038/sj.bjc.6603496

Ejemplares similares